Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Couchbase, Inc.BASE · Entity 74989 | 10% owner | July 26, 2021 | July 26, 2021 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | 10% owner | May 31, 2023 | June 02, 2023 |
| Markforged Holding CorpMKFG · Entity 80484 | 10% owner | July 14, 2021 | July 14, 2021 |
| VEECO INSTRUMENTS INCVECO · Entity 4322 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Couchbase, Inc.
Report date July 26, 2021 · Filed July 26, 2021
Jointly reported with NBVM GP, LLC, North Bridge Venture Partners 7, L.P., North Bridge Venture Partners VI L P, North Bridge Venture Management VI, L.P., North Bridge Venture Management 7, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy: North Bridge Venture Partners 7, L.P. | 2,689,172 |
Last balance in matching sequence
After 2021-07-26 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-07-26 · Conversion · Acquired 2,402,147 · Balance 2,594,381 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 3 · 2021-07-26 · Purchase · Acquired 94,791 · Balance 2,689,172 F4: In connection with the Issuer's initial public offering of Common Stock, NBVP 7 purchased additional shares of Common Stock from the underwriters at the initial public offering price as set forth herein. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectBy: North Bridge Venture Partners VI, L.P. | 1,987,084 |
Last balance in matching sequence
After 2021-07-26 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-07-26 · Conversion · Acquired 1,864,081 · Balance 1,946,459 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 4 · 2021-07-26 · Purchase · Acquired 40,625 · Balance 1,987,084 F5: In connection with the Issuer's initial public offering of Common Stock, NBVP VI purchased additional shares of Common Stock from the underwriters at the initial public offering price as set forth herein. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners 7, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-26 · Conversion · Disposed 643,708 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners VI, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-26 · Conversion · Disposed 643,708 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners 7, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-26 · Conversion · Disposed 498,927 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners VI, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-07-26 · Conversion · Disposed 498,927 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners 7, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-07-26 · Conversion · Disposed 317,901 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners VI, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-07-26 · Conversion · Disposed 317,901 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners 7, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-07-26 · Conversion · Disposed 201,031 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners VI, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-07-26 · Conversion · Disposed 86,156 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners 7, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-07-26 · Conversion · Disposed 93,999 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners VI, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-07-26 · Conversion · Disposed 40,285 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series F Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners 7, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-07-26 · Conversion · Disposed 131,840 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series F Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners VI, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-07-26 · Conversion · Disposed 56,502 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series G Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners 7, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-07-26 · Conversion · Disposed 477,888 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series G Preferred StockSEC Table II · derivative / convertible security | IndirectBy: North Bridge Venture Partners VI, L.P. | 0 |
Reported balance
After 2021-07-26 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2021-07-26 · Conversion · Disposed 204,809 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date. F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series E Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.05279880234039-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. Each share of Series G Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.06673317089756-for-one basis immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.
F2: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7, and NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors, and Richard A. D'Amore are the managing members of NBVM GP (collectively, the "Managing Members") and may be deemed to have shared voting and dispositive power over the shares held by NBVP 7. Each of NBVM 7, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI, and NBVM GP is the sole general partner of NBVM VI. The Managing Members are the managers of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F4: In connection with the Issuer's initial public offering of Common Stock, NBVP 7 purchased additional shares of Common Stock from the underwriters at the initial public offering price as set forth herein.
F5: In connection with the Issuer's initial public offering of Common Stock, NBVP VI purchased additional shares of Common Stock from the underwriters at the initial public offering price as set forth herein.
Lyra Therapeutics, Inc.
Report date May 31, 2023 · Filed June 02, 2023
Jointly reported with NBVM GP, LLC, NORTH BRIDGE VENTURE PARTNERS V A LP, NORTH BRIDGE VENTURE PARTNERS V-B LP, North Bridge Venture Partners VI L P, North Bridge Venture Management V, L.P., North Bridge Venture Management VI, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,259,301 |
Reported balance
After 2023-05-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-05-31 · Purchase · Acquired 403,858 · Balance 2,259,301 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F2: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,107,370 |
Reported balance
After 2023-05-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-05-31 · Purchase · Acquired 197,946 · Balance 1,107,370 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F3: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,521,745 |
Reported balance
After 2023-05-31 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-05-31 · Purchase · Acquired 1,203,612 · Balance 2,521,745 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F4: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Warrant to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2028-11-30 | IndirectSee footnote | 201,929 |
Reported balance
After 2023-05-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-05-31 · Purchase · Acquired 201,929 · Balance 201,929 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F2: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Warrant to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2028-11-30 | IndirectSee footnote | 98,973 |
Reported balance
After 2023-05-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-31 · Purchase · Acquired 98,973 · Balance 98,973 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F3: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Warrant to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2028-11-30 | IndirectSee footnote | 601,806 |
Reported balance
After 2023-05-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-05-31 · Purchase · Acquired 601,806 · Balance 601,806 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F4: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors.
F2: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F4: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Markforged Holding Corp
Report date July 14, 2021 · Filed July 14, 2021
Jointly reported with NBVM GP, LLC, North Bridge Venture Partners 7, L.P., North Bridge Venture Management 7, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy North Bridge Venture Partners 7, L.P. | 29,126,742 |
Reported balance
Holding disclosure · report date 2021-07-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 29,126,742 F1: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7 LP"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7 L.P. NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors post-closing of the Business Combination (as defined in footnote 2 below), and Richard A. D'Amore are the managers of NVBM GP (collectively, the "Managers"). Each of NBVM 7, NBVM GP and the Managers may be deemed to have shared voting and dispositive power over the shares held by NBVP 7 LP. Each of NBVM 7, NBVM GP and the Managers disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such shares for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein, if any. |
| Earnout SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2026-07-14 | IndirectBy North Bridge Venture Partners 7, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: On July 14, 2021 (the "Closing Date") one, the Issuer's predecessor, consummated the business combination (the "Business Combination") pursuant to the terms of the merger agreement dated as of February 23, 2021 by and among one, Caspian Merger Sub Inc., a Delaware corporation and MarkForged, Inc., a Delaware corporation. F3: Immediately prior to the effective time of the Business Combination on the Closing Date, NBVP 7 LP received the right to acquire 2,633,246 shares of the Issuer's Common Stock in connection with the Business Combination, (i) 1,436,316 of which will be released from escrow if the volume-weighted average price ("VWAP") of the Issuer for any 20 trading days in a consecutive 30-trading day period following the Closing Date is at least $12.50; and (ii) 1,196,930 of which will be released from escrow if the VWAP for any 20 trading days in a consecutive 30-day trading period following the Closing Date is at least $15.00. Upon a change of control or liquidation of the Issuer all such previously unearned shares will be issued. Any shares not eligible to be released within five years of the Closing Date will be forfeited and canceled. F1: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7 LP"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7 L.P. NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors post-closing of the Business Combination (as defined in footnote 2 below), and Richard A. D'Amore are the managers of NVBM GP (collectively, the "Managers"). Each of NBVM 7, NBVM GP and the Managers may be deemed to have shared voting and dispositive power over the shares held by NBVP 7 LP. Each of NBVM 7, NBVM GP and the Managers disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such shares for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reportable securities are owned directly by North Bridge Venture Partners 7, L.P. ("NBVP 7 LP"). North Bridge Venture Management 7, L.P. ("NBVM 7") is the sole general partner of NBVP 7 L.P. NBVM GP, LLC ("NBVM GP") is the sole general partner of NBVM 7. Each of Edward T. Anderson, a member of the Issuer's board of directors post-closing of the Business Combination (as defined in footnote 2 below), and Richard A. D'Amore are the managers of NVBM GP (collectively, the "Managers"). Each of NBVM 7, NBVM GP and the Managers may be deemed to have shared voting and dispositive power over the shares held by NBVP 7 LP. Each of NBVM 7, NBVM GP and the Managers disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such shares for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein, if any.
F2: On July 14, 2021 (the "Closing Date") one, the Issuer's predecessor, consummated the business combination (the "Business Combination") pursuant to the terms of the merger agreement dated as of February 23, 2021 by and among one, Caspian Merger Sub Inc., a Delaware corporation and MarkForged, Inc., a Delaware corporation.
F3: Immediately prior to the effective time of the Business Combination on the Closing Date, NBVP 7 LP received the right to acquire 2,633,246 shares of the Issuer's Common Stock in connection with the Business Combination, (i) 1,436,316 of which will be released from escrow if the volume-weighted average price ("VWAP") of the Issuer for any 20 trading days in a consecutive 30-trading day period following the Closing Date is at least $12.50; and (ii) 1,196,930 of which will be released from escrow if the VWAP for any 20 trading days in a consecutive 30-day trading period following the Closing Date is at least $15.00. Upon a change of control or liquidation of the Issuer all such previously unearned shares will be issued. Any shares not eligible to be released within five years of the Closing Date will be forfeited and canceled.
VEECO INSTRUMENTS INC
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,594 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Sale · Disposed 43,701 · Balance 112,594 F1: Reflects average weighted sale price. Actual sale prices ranged from $60.42 to $61.15 per share. The reporting person undertakes to provide, upon the request of the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects average weighted sale price. Actual sale prices ranged from $60.42 to $61.15 per share. The reporting person undertakes to provide, upon the request of the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EVERBRIDGE, INC.
Report date July 02, 2024 · Filed July 02, 2024
Section 16 reporting ended · disclosed 2024-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-07-02 transaction · row 1
1 source rowRow 1 · 2024-07-02 · Disposition to issuer · Disposed 25,415 · Balance 0 F1: On July 2, 2024, Project Emerson Merger Sub, Inc. ("Merger Sub") completed its merger (the "Merger") with and into the Issuer pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 29, 2024 (the "Merger Agreement"), by and among the Issuer, Everbridge Holdings, LLC (formerly known as Project Emerson Parent, LLC) ("Parent"), and Merger Sub, which amends and restates that certain Agreement and Plan of Merger, dated as of February 4, 2024, by and among the Issuer, Parent and Merger Sub. F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $35.00, without interest, subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 2, 2024, Project Emerson Merger Sub, Inc. ("Merger Sub") completed its merger (the "Merger") with and into the Issuer pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 29, 2024 (the "Merger Agreement"), by and among the Issuer, Everbridge Holdings, LLC (formerly known as Project Emerson Parent, LLC) ("Parent"), and Merger Sub, which amends and restates that certain Agreement and Plan of Merger, dated as of February 4, 2024, by and among the Issuer, Parent and Merger Sub.
F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $35.00, without interest, subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2020 Filed Jun 11, 2020 16:17 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | GiftCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035915 · doc4.xml · nonDerivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| May 31, 2020 Filed Jun 3, 2020 16:16 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-033971 · doc4.xml · derivative · entry 2 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On July 25, 2019, the reporting person was granted restricted stock units (RSUs). The RSUs vested on May 31, 2020. F3 · derivative.expiration_date: Not applicable Read SEC document |
| May 31, 2020 Filed Jun 3, 2020 16:16 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | Exercise / conversionCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-033971 · doc4.xml · nonDerivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 31, 2020 Filed Jun 2, 2021 16:31 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | Exercise / conversionCommon Stock | 723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037195 · doc4.xml · nonDerivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 13, 2020 Filed Jul 31, 2020 19:20 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | GrantRestricted Stock Unit · Derivative | 723 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044335 · doc4.xml · derivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Underlying: Common Stock · 723 shares Expires not disclosed F1 · derivative.exercise_date: Represents a grant of restricted stock units under the Everbridge, Inc. 2016 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Everbridge common stock. The restricted stock units are scheduled to vest on the earlier of May 31, 2021 or the end of the month of the 2021 annual stockholders' meeting, as long as the reporting person remains in the service of Everbridge through the respective vesting date. F2 · derivative.expiration_date: Not applicable Read SEC document |
| May 08, 2020 Filed May 8, 2020 20:38 UTC | VEECO INSTRUMENTS INC VECO · Entity 4322 | GrantCommon Stock | 10,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005620 · edgar.xml · nonDerivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,653 F1 · shares: These shares were awarded as restricted stock pursuant to the Veeco Instruments Inc. 2019 Stock Incentive Plan in consideration of services as a director. These shares are subject to certain restrictions which shall lapse on the earlier to occur of: (i) the date immediately preceding the date of the Company's 2021 Annual Meeting of Stockholders and (ii) the first anniversary of the award date. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 13,449 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 39 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,449 shares Expires 2030-01-10 F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 10,322 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 38 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 10,322 shares Expires 2030-01-10 F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 21,060 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 37 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 21,060 shares Expires 2030-01-10 F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,545,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 36 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,832 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,186,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 35 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 34,408 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,420,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 34 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 70,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,995,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 33 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 57,868 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,531,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 32 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: On May 5, 2020, NBVP VI exercised a warrant to purchase 13,449 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 7,255 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP VI. The Issuer also paid $15.13 to NBVP VI in lieu of a fractional share. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,124,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 31 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 90,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-4 Convertible Preferred Stock · Derivative | 2,391,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 30 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 69,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-4 Convertible Preferred Stock · Derivative | 1,835,743 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 29 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 53,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-4 Convertible Preferred Stock · Derivative | 3,745,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 28 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 108,614 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 2,929,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 27 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 84,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 2,248,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 26 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 65,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 4,587,608 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 25 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 133,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 2,088,772 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 24 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 60,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 1,603,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 23 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 46,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 3,270,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 22 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 94,849 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/C Convertible Preferred Stock · Derivative | 1,948,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 21 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 56,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/C Convertible Preferred Stock · Derivative | 1,495,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 20 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 43,377 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/C Convertible Preferred Stock · Derivative | 3,051,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 19 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 88,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/B Convertible Preferred Stock · Derivative | 1,647,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 18 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 47,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/B Convertible Preferred Stock · Derivative | 541,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 17 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 15,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/B Convertible Preferred Stock · Derivative | 1,105,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 16 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 32,066 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 1,725,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 15 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 50,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 567,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 14 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 16,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 1,157,670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 13 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 33,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 75,000 | $16.00 | $1,200,000.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 12 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 553,123 F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 57,561 | $16.00 | $920,976.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 11 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 381,618 F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 117,439 | $16.00 | $1,879,024.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 10 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 778,592 F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 7,255 | $16.00 | $116,080.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 9 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 478,123 F7 · kind: On May 5, 2020, NBVP VI exercised a warrant to purchase 13,449 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 7,255 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP VI. The Issuer also paid $15.13 to NBVP VI in lieu of a fractional share. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 13,449 | $8.63 | $116,064.87 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 8 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 485,378 F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 5,568 | $16.00 | $89,088.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 7 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 324,057 F6 · kind: On May 5, 2020, NBVP V-B exercised a warrant to purchsae 10,322 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 5,568 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP V-B. The Issuer also paid $9.14 to NBVP V-B in lieu of a fractional share. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 10,322 | $8.63 | $89,078.86 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 6 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 329,625 F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 11,360 | $16.00 | $181,760.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 5 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 661,153 F5 · kind: On May 5, 2020, NBVP V-A exercised a warrant to purchase 21,060 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 11,360 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP V-A. The Issuer also paid $12.20 to NBVP V-A in lieu of a fractional share. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 21,060 | $8.63 | $181,747.80 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 4 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 672,513 F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 471,929 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 3 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 471,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 319,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 2 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 319,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 651,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 1 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 651,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 16:44 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | GrantRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043498 · doc4.xml · derivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_date: Represents a grant of restricted stock units under the Everbridge, Inc. 2016 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Everbridge common stock. The restricted stock units are scheduled to vest on the earlier of May 31, 2020 or the end of the month of the 2020 annual stockholders meeting, as long as the reporting person remains in the service of Everbridge through the respective vesting date. F2 · derivative.expiration_date: Not applicable Read SEC document |
| June 04, 2019 Filed Jun 4, 2019 17:36 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | SaleCommon Stock | 2,500 | $76.52 | $191,307.50 |
DisclosureSEC source: 0001209191-19-034459 · doc4.xml · nonDerivative · entry 2 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 17:36 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-034459 · doc4.xml · derivative · entry 3 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On June 1, 2018, the reporting person was granted restricted stock units (RSUs). The RSUs vested on May 31, 2019. F3 · derivative.expiration_date: Not applicable Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 17:36 UTC | EVERBRIDGE, INC. EVBG · Entity 89241 | Exercise / conversionCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-034459 · doc4.xml · nonDerivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:19 UTC | VEECO INSTRUMENTS INC VECO · Entity 4322 | GrantCommon Stock | 9,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005709 · edgar.xml · nonDerivative · entry 1 DAMORE RICHARD A · CIK 0001206641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,264 F1 · shares: These shares were awarded as restricted stock pursuant to the Veeco Instruments Inc. 2019 Stock Incentive Plan in consideration of services as a director. These shares are subject to certain restrictions which shall lapse on the earlier to occur of: (i) the date immediately preceding the date of the Company's 2020 Annual Meeting of stockholders and (ii) the first anniversary of the award date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.